A Randomized, Blind, Parallel Controlled Phase I Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Population Aged 2 Years and Older
Latest Information Update: 26 Nov 2023
At a glance
- Drugs Pneumococcal 23 valent vaccine Ab and b Biotechnology (Primary) ; Polyvalent pneumococcal conjugate vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Ab&B Biotech; Jiangsu Zhonghui Yuantong Biotechnology
Most Recent Events
- 26 Apr 2023 New trial record